Researchers described the efficacy of tofacitinib in reducing pain in patients with inflammatory rheumatic and musculoskeletal diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
The role of mechanoinflammation in the pathogenesis of psoriatic disease and the presence of entheseal lesions as predictors of the onset of clinical joint disease gain support in a new study.
Researchers investigated serum microRNA levels in PsA and assessed the signature in therapeutic responder vs nonresponder patients with PsA.
Researchers compared definitions of high disease activity according to the ASDAS and BASDAI criteria in selecting patients for treatment with biologic disease-modifying antirheumatic drugs.
Researchers assessed the incidence of isotretinoin-triggered axial spondyloarthropathy in acne vulgaris patients based on clinical features and MRI findings and examined clinical and radiologic outcomes after drug withdrawal.
In this case study presented at ACTRIMS 2020, researchers reported on data from a patient with Crohn disease and ankylosing spondylitis who developed autoimmune encephalitis while receiving infliximab.
Recently released guidelines from Japan outline the factors that may influence the choice of biologic agents for treatment in patients with psoriasis.
Dr. Reddy’s Laboratories announced the launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, the generic equivalent to Vimovo®.
Disease activity in psoriatic arthritis may be positively correlated with body adiposity, saturated fat consumption, and serum cholesterol levels.
Researchers sought to determine the modifiable and nonmodifiable risk factors affecting anti-TNF response in axSpA.